(RTTNews) - On Thursday, Eli Lilly and Company (LLY) reported post-hoc analyses from the Phase 3 ATTAIN-1 trial showing that Foundayo was associated with significant reductions in predicted 10-year risks of type 2 diabetes and cardiovascular disease in adults with obesity or over
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.